Biotech Values

[ilpapa]

CTIC up 20% PM, don't own any

March 9 (Reuters) - CTI BioPharma Corp said its experimental blood cancer treatment achieved the main goal of a late-stage study.

Data from the study showed that the drug, pacritinib, was significantly better than the "best available therapy" as prescribed by the patients' physician to treat myelofibrosis.

Myelofibrosis is a form of blood cancer that makes the bone marrow produce too much of any type of blood cells.